Inhibición del RANK-L en la fisiopatología de la osteoporosis. Evidencias clínicas de su empleo.
Saved in:
| Title: | Inhibición del RANK-L en la fisiopatología de la osteoporosis. Evidencias clínicas de su empleo. |
|---|---|
| Authors: | Neyro, José Luis1,2 jlneyro@sego.es, Cancelo, María Jesús3, Palacios, Santiago4 |
| Source: | Ginecología y Obstetricia de México. Mar2013, Vol. 81 Issue 3, p146-157. 12p. 4 Diagrams, 3 Graphs. |
| Subjects: | OSTEOPOROSIS in women, THERAPEUTIC use of monoclonal antibodies, OSTEOCLAST inhibition, BONE cells, CLINICAL trial registries, THERAPEUTICS |
| Abstract (English): | The increase bone turnover is the most important fact at the physiopathology of postmenopausal osteoporosis. At the molecular level it is the increase of the RANK-L the principal mediator who allows the osteoclasts formation, survival and development of them. Multiple models have been in use in preclinical investigations for evaluating the effects of the inhibition of the RANKL, between which it is included on OPG’s over-expression in mice and transgenic mouse and by means of other models that include the treatment with recombinant OPG. The results of these studies show that RANKL’s inhibition improves the DMO as well as the geometry and resistance of the bone. Several references clinical trials have investigated the potential of denosumab as antiresorptive drug for the prevention and treatment of bone disease. It is a monoclonal antibody, the first fully human, which were recently published results of randomized clinical trials to eight years for increasing BMD in different locations and five years for the prevention of vertebral and hip fractures. We review the fundamentals of the mechanism of inhibition of RANK-L and the results of several clinical trials of Denosumab [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | El incremento del remodelado óseo, luego del déficit estrogénico, es uno de los mecanismos fundamentales de la osteoporosis postmenopáusica. Desde el punto de vista molecular es el incremento del RANK-L, el principal mediador que permite la formación, supervivencia y desarrollo de los osteoclastos. Para evaluar los efectos de la inhibición del RANK-L se han utilizado múltiples modelos, entre ellos la sobreexpresión de osteoprotegerina en ratones y ratas transgénicas y mediante otros modelos, que incluyen el tratamiento con osteoprotegerina recombinante. Los resultados de estos estudios muestran que la inhibición del RANK-L incrementa la densidad mineral ósea y mejora la geometría y resistencia del hueso. En diversos ensayos clínicos se ha investigado el potencial de denosumab como fármaco antirresortivo para tratar y prevenir las osteopatías. El denosumab es un anticuerpo monoclonal, totalmente humano, del que hace poco se publicaron los resultados de ensayos clínicos aleatorizados a ocho años en donde se demuestra el incremento de la densidad mineral ósea en diferentes localizaciones y a cinco años para prevenir fracturas vertebrales y de cadera. Se revisan los datos fundamentales del mecanismo de inhibición del RANK-L y los resultados de los diversos ensayos clínicos con denosumab. [ABSTRACT FROM AUTHOR] |
| Abstract (French): | L’augmentation du remodelage osseux, puis du déficit oestrogènes, est l’un des mécanismes fondamentaux de l’ostéoporose post-ménopausique. Depuis le point de vue moléculaire est l’augmentation du Rank-L, le médiateur principal qui permet la formation, de survie et développement des ostéoclastes. Pour évaluer les effets de l’inhibition de RANKL plusieurs modèles ont été utilisés, y compris la surexpression ostéoprotégérine chez des souris transgéniques et des rats par d’autres modèles, qui comprennent le traitement par l’ostéoprotégérine recombinant. Les résultats de ces études montrent que l’inhibition de la densité de RANK-L augmente minérale osseuse et de la géométrie et améliore la solidité des os. Dans plusieurs essais cliniques ont étudié le potentiel de denosumab en tant que médicament inhibiteur de la résorption pour traiter et prévenir les maladies osseuses. Le denosumab est un anticorps monoclonal entièrement humain, qui a récemment publié les résultats d’essais randomisés à huit années au cours desquelles la preuve de l’augmentation de la densité minérale osseuse à différents endroits et cinq ans pour prévenir les fractures vertébrales et de la hanche. Nous passons en revue les éléments fondamentaux du mécanisme d’inhibition de RANK-L et les résultats de divers essais cliniques observés avec dénosumab. [ABSTRACT FROM AUTHOR] |
| Abstract (Portuguese): | Remodelação óssea aumentada após a deficiência de estrogénio, é um dos mecanismos fundamentais da osteoporose pós-menopáusica. De um ponto de vista molecular é aumentado RANK-L, o que permite a formação de mediador principal e sobrevivência do desenvolvimento dos osteoclastos. Para avaliar os efeitos da inibição do RANK-L vários modelos foram utilizados, incluindo a superexpressão osteoprotegerina em ratos transgénicos e os ratos por outros modelos, que incluem o tratamento com osteoprotegerina recombinante. Os resultados destes estudos mostram que a inibição do sistema RANK-L aumenta a densidade mineral óssea e geometria e melhora a resistência do osso. Em vários estudos clínicos investigaram o potencial de denosumab como droga anti-reabsorção para o tratamento e prevenção de doenças dos ossos. Denosumab é um anticorpo monoclonal totalmente humano, que recentemente publicou os resultados de ensaios clínicos randomizados a oito anos em que a evidência do aumento na densidade mineral óssea em locais diferentes e de cinco anos para prevenir fraturas vertebrais e de quadril. Vamos rever os fundamentos do mecanismo de inibição de RANK-L e os resultados de vários ensaios clínicos com denosumab. [ABSTRACT FROM AUTHOR] |
| Copyright of Ginecología y Obstetricia de México is the property of Federacion Mexicana de Ginecologia y Obstetricia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 87714003 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Inhibición del RANK-L en la fisiopatología de la osteoporosis. Evidencias clínicas de su empleo. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Neyro%2C+José+Luis%22">Neyro, José Luis</searchLink><relatesTo>1,2</relatesTo><i> jlneyro@sego.es</i><br /><searchLink fieldCode="AR" term="%22Cancelo%2C+María+Jesús%22">Cancelo, María Jesús</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Palacios%2C+Santiago%22">Palacios, Santiago</searchLink><relatesTo>4</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Ginecología+y+Obstetricia+de+México%22">Ginecología y Obstetricia de México</searchLink>. Mar2013, Vol. 81 Issue 3, p146-157. 12p. 4 Diagrams, 3 Graphs. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22OSTEOPOROSIS+in+women%22">OSTEOPOROSIS in women</searchLink><br /><searchLink fieldCode="DE" term="%22THERAPEUTIC+use+of+monoclonal+antibodies%22">THERAPEUTIC use of monoclonal antibodies</searchLink><br /><searchLink fieldCode="DE" term="%22OSTEOCLAST+inhibition%22">OSTEOCLAST inhibition</searchLink><br /><searchLink fieldCode="DE" term="%22BONE+cells%22">BONE cells</searchLink><br /><searchLink fieldCode="DE" term="%22CLINICAL+trial+registries%22">CLINICAL trial registries</searchLink><br /><searchLink fieldCode="DE" term="%22THERAPEUTICS%22">THERAPEUTICS</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: The increase bone turnover is the most important fact at the physiopathology of postmenopausal osteoporosis. At the molecular level it is the increase of the RANK-L the principal mediator who allows the osteoclasts formation, survival and development of them. Multiple models have been in use in preclinical investigations for evaluating the effects of the inhibition of the RANKL, between which it is included on OPG’s over-expression in mice and transgenic mouse and by means of other models that include the treatment with recombinant OPG. The results of these studies show that RANKL’s inhibition improves the DMO as well as the geometry and resistance of the bone. Several references clinical trials have investigated the potential of denosumab as antiresorptive drug for the prevention and treatment of bone disease. It is a monoclonal antibody, the first fully human, which were recently published results of randomized clinical trials to eight years for increasing BMD in different locations and five years for the prevention of vertebral and hip fractures. We review the fundamentals of the mechanism of inhibition of RANK-L and the results of several clinical trials of Denosumab [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: El incremento del remodelado óseo, luego del déficit estrogénico, es uno de los mecanismos fundamentales de la osteoporosis postmenopáusica. Desde el punto de vista molecular es el incremento del RANK-L, el principal mediador que permite la formación, supervivencia y desarrollo de los osteoclastos. Para evaluar los efectos de la inhibición del RANK-L se han utilizado múltiples modelos, entre ellos la sobreexpresión de osteoprotegerina en ratones y ratas transgénicas y mediante otros modelos, que incluyen el tratamiento con osteoprotegerina recombinante. Los resultados de estos estudios muestran que la inhibición del RANK-L incrementa la densidad mineral ósea y mejora la geometría y resistencia del hueso. En diversos ensayos clínicos se ha investigado el potencial de denosumab como fármaco antirresortivo para tratar y prevenir las osteopatías. El denosumab es un anticuerpo monoclonal, totalmente humano, del que hace poco se publicaron los resultados de ensayos clínicos aleatorizados a ocho años en donde se demuestra el incremento de la densidad mineral ósea en diferentes localizaciones y a cinco años para prevenir fracturas vertebrales y de cadera. Se revisan los datos fundamentales del mecanismo de inhibición del RANK-L y los resultados de los diversos ensayos clínicos con denosumab. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (French) Group: Ab Data: L’augmentation du remodelage osseux, puis du déficit oestrogènes, est l’un des mécanismes fondamentaux de l’ostéoporose post-ménopausique. Depuis le point de vue moléculaire est l’augmentation du Rank-L, le médiateur principal qui permet la formation, de survie et développement des ostéoclastes. Pour évaluer les effets de l’inhibition de RANKL plusieurs modèles ont été utilisés, y compris la surexpression ostéoprotégérine chez des souris transgéniques et des rats par d’autres modèles, qui comprennent le traitement par l’ostéoprotégérine recombinant. Les résultats de ces études montrent que l’inhibition de la densité de RANK-L augmente minérale osseuse et de la géométrie et améliore la solidité des os. Dans plusieurs essais cliniques ont étudié le potentiel de denosumab en tant que médicament inhibiteur de la résorption pour traiter et prévenir les maladies osseuses. Le denosumab est un anticorps monoclonal entièrement humain, qui a récemment publié les résultats d’essais randomisés à huit années au cours desquelles la preuve de l’augmentation de la densité minérale osseuse à différents endroits et cinq ans pour prévenir les fractures vertébrales et de la hanche. Nous passons en revue les éléments fondamentaux du mécanisme d’inhibition de RANK-L et les résultats de divers essais cliniques observés avec dénosumab. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Portuguese) Group: Ab Data: Remodelação óssea aumentada após a deficiência de estrogénio, é um dos mecanismos fundamentais da osteoporose pós-menopáusica. De um ponto de vista molecular é aumentado RANK-L, o que permite a formação de mediador principal e sobrevivência do desenvolvimento dos osteoclastos. Para avaliar os efeitos da inibição do RANK-L vários modelos foram utilizados, incluindo a superexpressão osteoprotegerina em ratos transgénicos e os ratos por outros modelos, que incluem o tratamento com osteoprotegerina recombinante. Os resultados destes estudos mostram que a inibição do sistema RANK-L aumenta a densidade mineral óssea e geometria e melhora a resistência do osso. Em vários estudos clínicos investigaram o potencial de denosumab como droga anti-reabsorção para o tratamento e prevenção de doenças dos ossos. Denosumab é um anticorpo monoclonal totalmente humano, que recentemente publicou os resultados de ensaios clínicos randomizados a oito anos em que a evidência do aumento na densidade mineral óssea em locais diferentes e de cinco anos para prevenir fraturas vertebrais e de quadril. Vamos rever os fundamentos do mecanismo de inibição de RANK-L e os resultados de vários ensaios clínicos com denosumab. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Ginecología y Obstetricia de México is the property of Federacion Mexicana de Ginecologia y Obstetricia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=87714003 |
| RecordInfo | BibRecord: BibEntity: Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 12 StartPage: 146 Subjects: – SubjectFull: OSTEOPOROSIS in women Type: general – SubjectFull: THERAPEUTIC use of monoclonal antibodies Type: general – SubjectFull: OSTEOCLAST inhibition Type: general – SubjectFull: BONE cells Type: general – SubjectFull: CLINICAL trial registries Type: general – SubjectFull: THERAPEUTICS Type: general Titles: – TitleFull: Inhibición del RANK-L en la fisiopatología de la osteoporosis. Evidencias clínicas de su empleo. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Neyro, José Luis – PersonEntity: Name: NameFull: Cancelo, María Jesús – PersonEntity: Name: NameFull: Palacios, Santiago IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: Mar2013 Type: published Y: 2013 Identifiers: – Type: issn-print Value: 03009041 Numbering: – Type: volume Value: 81 – Type: issue Value: 3 Titles: – TitleFull: Ginecología y Obstetricia de México Type: main |
| ResultId | 1 |
